Wednesday, November 29, 2023 10:10:14 PM
Patient with high-risk R/R follicular lymphoma. Completed four 28-day cycles of CNTY-101 at the 100 million cell dose (DL1), first two administered following lymphodepletion, while the most recent two were administered without lymphodepletion. All doses of CNTY-101 with and without IL-2 or LD were well tolerated and demonstrated clinical benefit as defined as stable disease or better (per Lugano 2014 criteria). Responses were associated with tumour shrinkage and an ongoing CR of a duration of five months since the first CNTY-101 infusion. The PK data showed that CNTY-101 cells were detected after each infusion with comparable kinetics, with a limited duration in circulation. No measurable CDC-inducing functional ADA detected in any samples by data cut-off (including the first three cycles). Treatment was associated with changes in tumour microenvironment within eight days post-infusion, augmentation of adaptive T-cell responses, and tumour shrinkage.
Recent IPSC News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/15/2024 08:06:20 PM
- Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting • GlobeNewswire Inc. • 05/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:35:23 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:30:49 AM
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:13:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:13:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:13:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/06/2024 08:52:59 PM
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit • GlobeNewswire Inc. • 04/23/2024 11:00:00 AM
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics • GlobeNewswire Inc. • 04/11/2024 11:00:00 AM
- Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/08/2024 08:05:00 PM
- Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors • GlobeNewswire Inc. • 03/25/2024 11:00:00 AM
- Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/19/2024 11:00:00 AM
- Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/14/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 11:29:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:40:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 09:19:18 PM
- Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 03/05/2024 11:03:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:10:11 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 02/21/2024 06:04:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 09:18:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:21:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:21:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/06/2024 09:25:29 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM